The big story of the day was the collapse of Tom Daschle's nomination to head the Department of Health and Human Services. The Associated Press released the text of Daschle's withdrawal statement, which was quickly noted (1:16 p.m.) by Scott Hensley on Health Blog, at WSJ.com.
Reuter''s Susan Heavey forecast that Daschle's collapse could delay the selection of a new Food and Drug Administration commissioner. Among those Ms. Heavey turned to for comment were Ron Pollack, executive director of the consumer advocacy group, Families USA, and Diana Zuckerman, president of the advocacy group National Research Center for Women & Families.
Among possible contenders for the top FDA post, Ms. Heavey lists: Joshua Sharfstein, head of Baltimore's health department; Robert Califf, cardiologist at Duke University; Steven Nissen, cardiologist at Cleveland Clinic; and Susan Wood, former head of the FDA's Office of Women's Health.
Andrew Pollack of The New York Times is out online this afternoon with InterMune Stock Soars on Results of Lung Disease Drug Study, covering the market reaction to what may be the first drug to treat idiopathic pulmonary fibrosis, which afflicts 100,000 Americans each year.
InterMune shares jumped more than one-third in mid-afternoon trading today, as the company's CEO, Dan Welch, told securities analysts "we believe we have a very strong argument on behalf of patients." Pollack interviews Dr. Paul W. Noble, a professor at Duke University and co-chair of the committee that helped design the company's trial of the drug, called pirfenidone.
Dow Jones Newswires's Philadelphia-based pharma reporter, Peter Loftus, reports on the analysts conference call conducted by Merck & Co. CEO Richard Clark where the executive states that he is not ruling out "any transaction" Writes Loftus in Merck CEO: Eyeing 'Entire Spectrum' of Possible Acquisition: "[Clark's] comments Tuesday suggest Clark might be open to a larger combination with another traditional pharmaceutical company."
Loftus was back later in the afternoon with the 1,100-word Drug Makers Take Varying M&A Tacks In Wake of Pfizer's Move.
Also:
- Partner drugmakers Merck, Schering-Plough top forecasts on cost cuts despite light revenues -- (795 words) By Linda A. Johnson -- Associated Press
- Peanut Product Recall Took Company Approval -- (903 words) By Gardiner Harris -- New York Times
only this once will I prune my vineyard.the tree which I plantedAnd it came to pass that the Lord of the vineyard sent his servant
Posted by: beats by dr dre | 11/21/2011 at 09:28 PM
And the Lord of the vineyard said unto them, go to, and labor in the vineyard, with your mights. For behold, this is the last time that I shall nourish my vineyard
Posted by: Christian Louboutin Outlet | 11/21/2011 at 09:36 PM
For because ye have been diligent in labouring with me in my vineyard, and have kept my commandments, and have brought unto me again the natural fruit
Posted by: coach online outlet | 11/21/2011 at 09:41 PM
Of the increase of government and peace there is no end, upon the throne of David, and upon his kingdom to order it
Posted by: beats by dre | 11/24/2011 at 11:42 PM
But at present there was nothing more to be said. Mr. Woodhouse very soon followed them into the drawing-room.
Posted by: burberry outlet | 01/09/2012 at 05:22 PM